Andrew S Judd - JoVE Visualize

Showing results (21-30 of 23) with videos related to

Pageof 3

Sort By:

You have reached the last page of results.This site can display upto 23 results.

ACS Medicinal Chemistry Letters|October 16, 2020

Discovery of A-1331852, a First-in-Class, Potent, and Orally-Bioavailable BCL-XL InhibitorLe Wang, George A Doherty, Andrew S Judd, et al.

Journal of Medicinal Chemistry|September 16, 2005

Discovery and characterization of aminopiperidinecoumarin melanin concentrating hormone receptor 1 antagonistsPhilip R Kym, Rajesh Iyengar, Andrew J Souers, et al.

Science Advances|October 4, 2024

BCL-XL-targeting antibody-drug conjugates are active in preclinical models and mitigate on-mechanism toxicity of small-molecule inhibitorsAndrew S Judd, Bhupinder Bawa, Wayne R Buck, et al.

Pageof 3

Showing results (21-30 of 23) with videos related to

Sort By:

Pageof 3

You have reached the last page of results.This site can display upto 23 results.

ACS Medicinal Chemistry Letters|October 16, 2020

Discovery of A-1331852, a First-in-Class, Potent, and Orally-Bioavailable BCL-XL InhibitorLe Wang, George A Doherty, Andrew S Judd, et al.

Journal of Medicinal Chemistry|September 16, 2005

Discovery and characterization of aminopiperidinecoumarin melanin concentrating hormone receptor 1 antagonistsPhilip R Kym, Rajesh Iyengar, Andrew J Souers, et al.

Science Advances|October 4, 2024

BCL-XL-targeting antibody-drug conjugates are active in preclinical models and mitigate on-mechanism toxicity of small-molecule inhibitorsAndrew S Judd, Bhupinder Bawa, Wayne R Buck, et al.

Pageof 3